Remiges Ventures

Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Developer of therapeutic treatment and optical sensor protein designed for intractable eye diseases using the latest technology. The company's chimeric rhodopsin genes overcome the weakness of conventional rhodopsins and keep them working with high sensitivity for patients, helping doctors treat eye diseases.

Capacity Bio is a therapeutics company that is focused on mitophagy. Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondrial quality control in disease.

Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.

Cyrano Therapeutics, Inc., founded in 2014 and headquartered in Washington, D.C., develops therapeutic solutions aimed at addressing taste and smell disorders. The company's primary offering is an intranasal product, CYR-001, which repurposes the approved molecule Theophylline to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, the treatment demonstrated significant efficacy, with eight out of ten patients showing notable improvements within two weeks and no reported side effects. In addition to the therapy, Cyrano Therapeutics provides a diagnostic kit to assess and quantify the severity of sensory loss, which can assist healthcare providers, particularly otolaryngologists, in managing care for affected individuals, including cancer patients undergoing chemotherapy who may experience sensory changes.

Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Tranquis Therapeutics, Inc., a biotechnology company, engages in developing immuno-therapeutics for neurodegenerative and aging-related diseases. Its TQS-168 is a therapeutic candidate that targets underlying myeloid immune cell dysfunction that is linked to a variety of nervous system disorders. Its solution is used to treat amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. The company was incorporated in 2016 and is based in San Mateo, California.

OMEICOS Therapeutics GmbH is a biotechnology company focused on developing innovative therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. Established in 2013 and headquartered in Berlin, Germany, the company is pioneering a first-in-class small molecule that leverages a unique mode of action based on natural metabolites of omega-3 fatty acids. These metabolites exhibit strong anti-arrhythmic properties by activating an endogenous cardio-protective signaling pathway, which not only stabilizes heart rhythm but also aims to provide curative effects by preventing electrical and structural remodeling of the heart. OMEICOS' approach is designed to offer safe and effective treatment options for patients with cardiovascular conditions, while also addressing inflammatory diseases and other indications.

ENB Therapeutics, LLC develops small molecule inhibitors to treat melanoma and other cancers. The product includes ENB-001 that restores the ability of T-cells to infiltrate tumors and inhibits metastasis. The company was incorporated in 2015 and is based in New York, New York.

KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.

OMEICOS Therapeutics GmbH is a biotechnology company focused on developing innovative therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. Established in 2013 and headquartered in Berlin, Germany, the company is pioneering a first-in-class small molecule that leverages a unique mode of action based on natural metabolites of omega-3 fatty acids. These metabolites exhibit strong anti-arrhythmic properties by activating an endogenous cardio-protective signaling pathway, which not only stabilizes heart rhythm but also aims to provide curative effects by preventing electrical and structural remodeling of the heart. OMEICOS' approach is designed to offer safe and effective treatment options for patients with cardiovascular conditions, while also addressing inflammatory diseases and other indications.

Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

InFlectis BioScience is a drug discovery company based in Nantes, France, established in 2013. The company specializes in developing small molecule drugs that target the unfolded protein response, aiming to address misfolded protein disorders linked to neurodegenerative and age-related diseases. By focusing on the cellular defense system against misfolded proteins, InFlectis BioScience seeks to modulate key proteins involved in maintaining endoplasmic reticulum (ER) proteostasis, which is essential for cellular function and survival. The company’s innovative approach helps to safeguard cellular integrity by managing ER stress, a condition that arises when the folding capacity of the ER is compromised. Through its research and development efforts, InFlectis BioScience strives to advance preclinical-stage products that can enhance patient care while maximizing the commercial potential of its offerings.